Urovant Sciences (NASDAQ:UROV) released its quarterly earnings data on Tuesday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.02), Morningstar.com reports.

NASDAQ UROV opened at $7.54 on Wednesday. The company’s fifty day moving average price is $8.24. The company has a market cap of $227.55 million and a PE ratio of -1.70. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.34 and a quick ratio of 8.34. Urovant Sciences has a 1-year low of $4.05 and a 1-year high of $14.49.

Several research firms recently issued reports on UROV. HC Wainwright set a $28.00 price objective on Urovant Sciences and gave the company a “buy” rating in a research report on Monday, June 24th. JPMorgan Chase & Co. set a $24.00 price objective on Urovant Sciences and gave the company a “buy” rating in a research report on Friday, June 14th. ValuEngine raised Urovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research cut Urovant Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, May 22nd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $21.63.

In other news, major shareholder Andrew Lo purchased 18,204 shares of the stock in a transaction dated Wednesday, June 19th. The shares were purchased at an average cost of $8.32 per share, with a total value of $151,457.28. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Holdings Ltd. Dexxon purchased 11,608 shares of the stock in a transaction dated Friday, May 17th. The shares were purchased at an average cost of $7.10 per share, for a total transaction of $82,416.80. The disclosure for this purchase can be found here. Insiders have bought a total of 167,952 shares of company stock worth $1,330,019 over the last three months. Insiders own 2.40% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UROV. Barclays PLC bought a new position in shares of Urovant Sciences during the 4th quarter valued at $37,000. Two Sigma Investments LP bought a new position in Urovant Sciences in the 4th quarter worth $72,000. FMR LLC raised its holdings in Urovant Sciences by 11.1% in the 4th quarter. FMR LLC now owns 1,332,701 shares of the company’s stock worth $8,782,000 after purchasing an additional 132,701 shares during the period. Marshall Wace LLP bought a new position in Urovant Sciences in the 1st quarter worth $325,000. Finally, Marshall Wace North America L.P. bought a new position in Urovant Sciences in the 1st quarter worth $49,000. 21.91% of the stock is currently owned by hedge funds and other institutional investors.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

See Also: What is the quiet period?

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.